ESPRIT 2002

1 Treatments

Studied treatment  oestradiol valerate 2 mg daily

Control treatment  placebo

Concomittant treatments  -

Age (years)  -

Age (years)  62.6 y

2 Patients

Patients  postmenopausal women, age 50-69 years who had survived a first myocardial infarction

Inclusion criteria  women aged 50–69 years; diagnostic criteria for myocardial infarction, discharged alive from hospital within 31 days of admission, no previous documented myocardial infarction

Exclusion criteria  use of HRT or vaginal bleeding in the 12 months before admission; history of breast, ovarian, or endometrial carcinoma; or active thrombophlebitis or a history of deep-vein thrombosis or pulmonary embolism, acute or chronic liver disease, Rotor syndrome, Dubin-Johnson syndrome, or severe renal disease

type of prevention  (secondary prevention

diabetes (%)  15%

hypertension (%)  44%

hyperlipidemia (%)  -

BMI (kg/m²)  26.7

Hysterectomy (%)  24%

Oophorectomy (%)  -

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  35
Geographical area  England and Wales

Sizes  513/504

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>10/513</td>
<td>6/504</td>
<td>1.64</td>
<td>[0.59; 4.54]</td>
</tr>
<tr>
<td>venous thromboembolism</td>
<td>2/513</td>
<td>1/504</td>
<td>1.96</td>
<td>[0.18; 21.74]</td>
</tr>
<tr>
<td>PE</td>
<td>3/513</td>
<td>3/504</td>
<td>0.98</td>
<td>[0.20; 4.89]</td>
</tr>
<tr>
<td>all cause death</td>
<td>32/513</td>
<td>39/504</td>
<td>0.81</td>
<td>[0.50; 1.31]</td>
</tr>
<tr>
<td>CV events</td>
<td>-/513</td>
<td>-/504</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Cv death</td>
<td>21/513</td>
<td>30/504</td>
<td>0.69</td>
<td>[0.39; 1.22]</td>
</tr>
<tr>
<td>Coronary events (CHD)</td>
<td>62/513</td>
<td>61/504</td>
<td>1.00</td>
<td>[0.68; 1.46]</td>
</tr>
<tr>
<td>non fatal MI</td>
<td>41/513</td>
<td>31/504</td>
<td>1.30</td>
<td>[0.80; 2.11]</td>
</tr>
</tbody>
</table>

5 References